William Blair Raises Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at William Blair boosted their Q3 2025 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Wednesday, April 2nd. William Blair analyst S. Corwin now expects that the company will post earnings of $1.84 per share for the quarter, up from their prior estimate of $1.82. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q3 2025 earnings at $1.84 EPS, Q3 2026 earnings at $2.57 EPS, Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.92 EPS and Q4 2026 earnings at $2.92 EPS.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 EPS.

A number of other equities analysts have also weighed in on KRYS. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and an average price target of $220.00.

Krystal Biotech Stock Down 3.8 %

KRYS opened at $171.30 on Friday. The business’s 50 day moving average is $173.27 and its two-hundred day moving average is $173.18. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in Krystal Biotech by 346.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company’s stock worth $1,899,000 after acquiring an additional 8,098 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Krystal Biotech by 3.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after buying an additional 153 shares in the last quarter. Hilltop Holdings Inc. bought a new stake in Krystal Biotech in the third quarter worth about $209,000. State Street Corp raised its position in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Krystal Biotech by 15.1% in the 3rd quarter. Wellington Management Group LLP now owns 12,680 shares of the company’s stock valued at $2,308,000 after acquiring an additional 1,660 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).